Spike protein evolution in the SARS-CoV-2 Delta variant of concern: a case series from Northern Lombardy

References

• Baral P, Bhattarai N, Hossen ML, et al. Mutation-induced changes in the receptor-binding interface of the SARS-CoV-2 Delta variant B.1.617.2 and implications for immune evasion. Biochem Biophys Res Commun. 2021;574:14–19.
   Web of Science ®Google Scholar
• Planas D, Veyer D, Baidaliuk A, et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature. 2021;596(7871):276–280.
   PubMed Web of Science ®Google Scholar
• Baj A, Novazzi F, Ferrante FD, et al. Introduction of SARS-COV-2 C.37 (WHO VOI lambda) from Peru to Italy. J Med Virol. 2021;93(12):6460–6461.
   Web of Science ®Google Scholar
• Thornlow B, Hinrichs AS, Jain M, et al. A new SARS-CoV-2 lineage that shares mutations with known variants of concern is rejected by automated sequence repository quality control. bioRxiv. 2021, 2021.04.05.438352.
   Google Scholar
• Chaudhari A, Kumar D, Joshi DM, et al. E156/G and Arg158, Phe-157/del mutation in NTD of spike protein in B.1.167.2 lineage of SARS-CoV-2 leads to immune evasion through antibody escape. bioRxiv. 2021, 2021.06.07.447321.
   Google Scholar
• Arora P, Krueger N, Kempf A, et al. Increased lung cell entry of B.1.617.2 and evasion of antibodies induced by infection and BNT162b2 vaccination. BioRxiv. 2021, 2021.06.23.449568.
   Google Scholar
• Hoffmann M, Hofmann-Winkler H, Krueger N, et al. SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination. Cell Rep. 2021;36(3):109415.
   PubMed Web of Science ®Google Scholar
• Ferreira I, Datir R, Papa G, et al. SARS-CoV-2 B.1.617 emergence and sensitivity to vaccine-elicited antibodies. BioRxiv. 2021, 2021.05.08.443253.
   Google Scholar
• Mohandas S, Yadav PD, Shete AA, et al. SARS-CoV-2 Delta variant pathogenesis and host response in Syrian hamsters. Viruses. 2021;13(9):1773.
   PubMed Web of Science ®Google Scholar
• Farinholt T, Qin X, Meng Q, et al. Transmission event of SARS-CoV-2 Delta variant reveals multiple vaccine breakthrough infections. BMC Med. 2021;19(1):1–6.
   Web of Science ®Google Scholar
• Mishra A, Kumar N, Bhatia S, et al. SARS-CoV-2 Delta variant among Asiatic Lions, India. Emerg Infect Dis. 2021;27(10):2723–2725.
   Web of Science ®Google Scholar
• Li B, Deng A, Li K, et al. Viral infection and Transmission in a large well-traced outbreak caused by the Delta SARS-CoV-2 variant. MedRxiv. 2021, 2021.07.07.21260122.
   Google Scholar
• Tada T, Zhou H, Samanovic MI, et al. Comparison of neutralizing antibody titers elicited by mRNA and adenoviral vector vaccine against SARS-CoV-2 variants. bioRxiv. 2021.
   Google Scholar
• Tada T, Zhou H, Dcosta BM, et al. The Spike proteins of SARS-CoV-2 B.1.617 and B.1.618 variants identified in India provide partial Resistance to vaccine-elicited and therapeutic monoclonal antibodies. BioRxiv. 2021, 2021.05.14.444076.
   Google Scholar
• Vacharathit V, Aiewsakun P, Manopwisedjaroen S, et al. A. CoronaVac induces lower neutralising activity against variants of concern than natural infection. Lancet Infect Dis. 2021 Oct;21(10):1352–1354.
   PubMed Web of Science ®Google Scholar
• Yadav PD, Sapkal GN, Ella R, et al. Neutralization of Beta and Delta variant with sera of COVID-19 recovered cases and vaccinees of inactivated COVID-19 vaccine BBV152/Covaxin. J Travel Med. 2021 October;28(7).
   Web of Science ®Google Scholar
• Zhang L, Huynh T, Luan B.  in silico  assessment of antibody drug Resistance to bamlanivimab of SARS-CoV-2 variant B.1.617. bioRxiv. 2021, 2021.05.12.443826.
   Google Scholar
• Ryu D-K, Woo H-M, Kang B, et al. The in vitro and in vivo efficacy of CT-P59 against Gamma, Delta and its associated variants of SARS-CoV-2. Biochem Biophys Res Commun. 2021 Nov 12(578):91–96.
   PubMed Web of Science ®Google Scholar
• Edara V-V, Lai L, Sahoo M, et al. Infection and vaccine-induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant. bioRxiv. 2021, 2021.05.09.443299.
   Google Scholar
• Liu J, Liu Y, Xia H, et al. BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants. Nature. 2021;596:273–275.
   PubMed Web of Science ®Google Scholar
• Wall EC, Wu M, Harvey R, et al. Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination. The Lancet. 2021;397(10292):2331–2333.
   PubMed Web of Science ®Google Scholar
• Edara V-V, Pinsky BA, Suthar MS, et al. Infection and vaccine-induced neutralizing-antibody responses to the SARS-CoV-2 B.1.617 variants. N Engl J Med 2021; 385:664–666.
   Web of Science ®Google Scholar
• Carreno JM, Alshammary H, Singh G, et al. Reduced neutralizing activity of post-SARS-CoV-2 vaccination serum against variants B.1.617.2, B.1.351, B.1.1.7+E484 K and a sub-variant of C.37. medRxiv. 2021, 2021.07.21.21260961.
   Google Scholar
• Choi A, Koch M, Wu K, et al. Serum neutralizing activity of mRNA-1273 against SARS-CoV-2 variants. J Virol. 2021 Sep 22:JVI0131321.
   Web of Science ®Google Scholar
• Yadav P, Sapkal GN, Abraham P, et al. Neutralization potential of Covishield vaccinated individuals against B.1.617.1. Clinical Infectious Diseases, 2021; ciab483.
   Google Scholar
• Sapkal GN, Yadav PD, Sahay RR, et al. Neutralization of Delta variant with sera of Covishield vaccinees and COVID-19 recovered vaccinated individuals. J Travel Med. 2021 Oct 11;28(7):taab119.
   Web of Science ®Google Scholar
• Jongeneelen M, Kaszas K, Veldman D, et al. Ad26.COV2.S elicited neutralizing activity against Delta and other SARS-CoV-2 variants of concern. bioRxiv. 2021, 2021.07.01.450707.
   Google Scholar
• Hu J, Wei X-Y, Xiang J, et al. Reduced neutralization of SARS-CoV-2 B.1.617 variant by inactivated and RBD-subunit vaccine. bioRxiv. 2021, 2021.07.09.451732.
   Google Scholar
• Yadav PD, Sahay RR, Sapkal G, et al. Comparable neutralization of SARS-CoV-2 Delta AY.1 and Delta in individuals sera vaccinated with BBV152. J Travel Med. 2021; taab154.
   Google Scholar